Asieris Pharmaceuticals (SHA: 688176), a China-based specialist in urogenital cancer treatments, has announced that it has received clinical clearance from the U.S. Food and Drug Administration (FDA) for its in-house developed ubiquitin specific peptidase 1 (USP1) inhibitor, APL-2302, for the treatment of advanced solid tumors.
Preclinical studies have indicated that APL-2302 demonstrates robust in vitro and in vivo anti-tumor activity when used as a monotherapy or in combination with other treatments. The drug operates on the principle of “synthetic lethality” to exert its anti-tumor effects and holds the potential to emerge as a novel therapeutic option for patients with advanced solid tumors, including breast cancer, ovarian cancer, prostate cancer, and others, that test positive for specific biomarkers such as BRCA mutations.- Flcube.com
